Schizophrenia

Schizophrenia

  • April 2016 •
  • 284 pages •
  • Report ID: 4035435 •
  • Format: PDF
Schizophrenia’s unmet needs can be turned into key commercial opportunities to drive the growth of the market.

This report addresses the following questions:

- What will be the key growth drivers of the schizophrenia market?
- Which will be the new leading brands in schizophrenia, now that former market-leader Abilify faces generic competition?
- What are the main trends in late-stage drug development for schizophrenia, and which candidates have shown promise in clinical trials?
- Which are the most clinically and commercially attractive brands in the schizophrenia market?
- How are schizophrenia patients currently managed, and which are the key treatment challenges they encounter?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.